Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. février 2022 RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors Roulston A, Zimmermann M, Papp R, et al. Molecular Cancer Therapeutics juin 2020 Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity Sokolova AO, Yu EY, Cheng HH Clinical Cancer Research mai 2020 Identifying functional loss of ATM gene in patients with advanced cancer Pilie PG, Gheeya JS, Kyewalabye K, et al. ASCO février 2020 Analyse pan-cancer de génomes entiers Consortium ICGC/TCGA pour l'analyse pancancer du génome entier Nature février 2020 Pan-cancer analysis of whole genomes ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Nature janvier 2020 CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions Su D, Feng X, Colic M, et al. ScienceDirect novembre 2019 Synthetic lethality as an engine for cancer drug target discovery Huang A, Garraway LA, Ashworth A, Weber B Nature Reviews Drug Discover juin 2019 A CRISPR Way to Identify Cancer Targets Hahn WC New England Journal of Medicine mai 2019 First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors De Bono JS, Shao DP, Caldwell R, et al. Journal of Clinical Oncology avril 2018 Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Knijenburg TA, Wang LH, Zimmermann MT, et al. Cell Reports 12345 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
